REG - Deepverge PLC - Updates on Labskin, Modern Water, Skin Trust Club

DeepvergeAnnouncement

31/03/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210331:nRSe0320Ua&default-theme=true

RNS Number : 0320U  Deepverge PLC  31 March 2021

31 March 2021

 

DeepVerge PLC

("DeepVerge" or "Company")

 

DeepVerge Investor Presentation

 

Project Updates on Labskin, Modern Water, Skin Trust Club

 

 

DeepVerge (LSE:DVRG.L), the environmental and life science AI company, is
pleased to provide an update ahead of Gerry Brandon, the CEO of DeepVerge
presentation relating to Project Updates - Labskin, Skin Trust Club, Modern
Water - Wastewater & Breath Test via the Investor Meet Company platform
on 31st Mar 2021 at 1:30pm BST.

·      Incredibly busy period with continued growth across all business
divisions:

§ FY 2020 unaudited - organic growth - £4.4m

§ FY 2020 aggregated revenues £6.1m (unaudited)

§ Dec 2020: Cash & Cash Equivalent £2.97m

§ Post Dec 2020: £650,740 in exercised warrants

·      FY 2021 guidance remains at £10m with £3.6m already received in
Modern Water orders in Q1

·      The Labskin Division has sealed its reputation as a leading
diagnostics partner with global partners and new service offerings

§ We work with 18 of the top 20 global pharma companies.

§ Virtual clinical trials with remote collection of human volunteer's skin
microbiome

•     New solution for the collection of volunteer microbiomes to allow
for lab controlled clinical trials of advanced skin models (pigmented, acne,
atopic dermatitis, psoriasis) and human microbiomes

•     As the data bank of remote volunteers grow the higher the accuracy
and increased reliability of virtual product testing can be provided to
clients eliminating early human trial and error testing and faster time to
market

•     Building of a data repository to allow AI modelling of skin
conditions and ingredient effects

§ Launch of Skin Trust Club Artificial Intelligent (A.I.) Skincare App and
Home Test Kit

•     2,000 members in the Alpha test with more than 5,000 before we
stopped accepting for the Beta of which we will throttle back to complete.

•     Self-administered skin swab from home-test-kit allows the clinical
trial or Skin Trust Club participant to conduct a simple test without
interaction

•     DNA test that generates a report consumers can use to manage their
custom skincare regimen. Analysis of skin attributes provides information to
create hundreds of different product combinations to suit a persons unique
skin microbiome

•     As the data bank of remote volunteers grow the higher the accuracy
and increased reliability of virtual product testing can be provided to
clients eliminating early human trial and error testing and faster time to
market

·      Environmental Health division also continues to grow apace with
new equipment, solutions, labs and services creating a strong $5m (£3.7m)
sales pipe for Microtox and Microtrace in Q1 alone:

§ New equipment rolling off production lines on three continents to meet
demand across the Microtox and MicroTrace range with new range of real-time
surveillance services in Water Quality Monitoring

§ New solutions to detect contaminants of concern and forever chemicals
through Microsaic systems, mass spectroscopy-based identification systems and
our work with the Aptamer Group

§ Two New Containment Level 3 (Virus) level labs at our York UK facility

§ New services to detect dangerous pathogens, including contagious infections
as well as community detection of opioids

 

·      Initial data from ongoing Phase III COVID-19 detection studies
demonstrates ability to identify and detect the virus

§ Public Health England access to the SARS-CoV-2 virus at Category 3 lab with
University of Aberdeen, Genoa, Italy and Liverpool University

•     Identified the virus S-Protein in quantities at 40 femtogram per
millilitre ("Fg/mL")

•     Close to 100% sensitivity and specificity on DeepVerge's
Microtox® BT nano-optofluidic chip

§ 40 subject breath test clinical trial concluded at Royal College of
Surgeons, Ireland

•     16 independently confirmed as COVID-19 positive with PCR tests

•     Breath samples were tested on the Microtox® BT nano-optofluidic
chip surface with Affimer® reagents ("Avacta Group") and Optimers ("Aptamer
Group")

•     Detection of the live virus confirmed indicating 9 times increase
in digital spectrum signal on the Microtox® BT compared to control

•     Microtox® BT delivered results in under 60 seconds from breath
samples

§ Subject to completion of additional human trials, the Microtox® BT would
be expected to meet the criteria for UK, MHRA's Target Product Profile Rapid
Breath Test which would enable us to roll out the COVID19 and other pathogen
breath tests later this year

·      2021 looks to be a promising year for DeepVerge with progress
ramping up and particularly strong interest from China for our Microtox
products, as well as our new Labskin offerings.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to
meet DEEPVERGE PLC via:

https://www.investormeetcompany.com/deepverge-plc/register-investor
(https://www.investormeetcompany.com/deepverge-plc/register-investor)

Investors who already follow DEEPVERGE PLC on the Investor Meet Company
platform will automatically be invited.

 

 

 DeepVerge plc                                   Gerry Brandon               +44 (0) 734 0055 648

 SPARK Advisory Partners Limited                 Neil Baldwin/Andrew Emmott  +44 (0) 113 370 8974

 (Nominated Adviser)

 Turner Pope Investments (TPI) Limited (Broker)  Andy Thacker/Zoe Alexander  +44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that
develops and applies AI and IoT technology to analytical instruments and the
data they generate, for the analysis and identification of bacteria, virus and
toxins. DeepVerge is utilising artificial intelligent data analytics to prove
scientifically the impact of skincare product claims on the skin microbiome
for clients including most of the top 20 global cosmetic companies and to
detect remotely, and identify in real-time, dangerous pathogens in wastewater
treatment plants, drinking water, rivers, lakes and reservoirs.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSDEFASEFSEFD